Description
Cygnus Technologies EndonucleaseGTP® ELISA Kit is a sensitive and specific assay to detect and quantify residual endonuclease impurity in recombinant viral vector and vaccine preparations. Expression of recombinant viral vectors and vaccines in mammalian cell culture is a cost-effective method for production of commercial quantities of gene therapy and vaccine biologics. The manufacturing and purification process of these products leaves the potential for contamination by endonuclease enzyme often used to remove endogenous host cell DNA and RNA, as well as unincorporated plasmid DNA from viral vector production. It is desirable to reduce endonuclease contamination to the lowest levels practical.
Cygnus EndonucleaseGTP® ELISA kit is based on antibodies generated and affinity purified against a genetically engineered endonuclease from Serratia marcescens. With a detection limit of ~60 pg/ml, it is a sensitive and specific method to aid in purification process development, process control, routine quality control and product release testing. The kit uses a simple simultaneous protocol where samples containing endonuclease are reacted simultaneously with a HRP-labeled anti-endonuclease detection antibody in microtiter strips coated with an affinity purified capture anti-endonuclease antibody.
The EndonucleaseGTP® ELISA Kit contains all components to evaluate the presence of endonuclease impurities in 96 samples, including a set of calibrated endonuclease standards. It is suitable for the detection of genetically engineered endonucleases such as Benzonase Nuclease and DENARASE.
*Benzonase Nuclease is a registered trademark of Merck KGaA DENARASE is a registered trademark of c-LEcta.
Product Information
Kit Components
Product Insert
Supporting Documents
Product FAQs
- Can the ELISA Protocol in the Product Insert be Modified?
- How do I Maintain Quality Control of ELISA?
- What About Automation of Immunoassays?
- What is the Storage and Stability of ELISA Kits?
- What Issues to Consider When Diluting Samples?
- Why Perform Dual Wavelength Analysis?
Related Products
Related Products
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
GM实验：试剂说明书上要求20分钟显色，10分钟的时候看一下，差不多就可以加终止液，但是我的标曲显色特别快，2分钟最低浓度蓝色就就深了，此时样本颜色还很浅很浅，我只能一块儿加终止液。所以，标曲显色过快，可能是什么原因？
（ps:第一列是标曲，后面是样本）
1、直接竞争，标记抗原，与检测样品中的抗原竞争抗体。
2、间接竞争，标记抗体，固相抗原与液相抗原（样品）竞争标记抗体。
3、定义
间接竞争法的模型：包被抗原，用HRP-抗体与样本一起加入。样本中的Ag与Solid-Ag竞争HRP-Ab，固相吸附的HRP-Ab与样本中的Ag浓度成反比。
直接竞争法的模型：包被抗体，用HRP-抗原与样本一起加入。样本中的Ag与HRP-Ag竞争Solid-Ab，固相吸附的HRP-Ag与样本中的Ag浓度成反比。
4、竞争法的理论基础：是限量抗体。只有在限量抗体基础上，两种抗原才会形成竞争关系。
5、、间接竞争法具备较高灵敏度原因。
直接竞争法里，标记抗原与待测抗原均是液相，与抗体的结合机会是一样的，例如有1份标记抗原与1份待测抗原竞争1份抗体，那么有50%的标记抗原能与抗体结合，所以标记抗原的相对结合率为50%。间接法里，固相抗原与抗体的接触面积较小，固相抗原与待测抗原的结合抗体机会是不平等的，接近顺序饱和法，即只有与待测抗原结合剩余的抗体才会与固相抗原结合，同样有1份固相抗原与1份待测抗原竞争1份抗体时，基本上抗体会被待测抗原中和掉，与固相抗原结合的抗体非常少。固相抗原的相对结合率为0%。因此，间接法的抑制曲线斜率会大于竞争法。
因为抑制率越大则斜率越大，从而灵敏度越大。（假设零管变异5%，以两倍SD为灵敏度限，则为90%相对结合率，则间接法可以在较低的待测抗原浓度达到这一相对结合率，因此灵敏度要高。）
在进行系统放大时，间接法一般可以使用酶标二抗。因为二抗可以针对抗体的多个部位，所以存在放大效应，从而能提高间接法的灵敏度。直接法一般难以进行放大，常用的有生物 素化抗原与酶标亲和素，但模式上似乎不存在放大效应。
6、间接法的高灵敏度难以实现的原因：
双抗体 夹心的免放（IRMA）模式刚出现时，也被模型证明灵敏度优于竞争法的放免（RIA），原因也是较大的斜率，但是IRMA的高灵敏度一直到单抗发展后才得以实现。
采用抗-HBe抗体包被反应板，加入校准品及被测样本，同时加入定量HBeAg中和抗原，经过振荡孵育,洗板后再加入铕标记的抗-HBe，若标本中抗-HBe浓度高，HBeAg将被大量中和，使最后形成的抗-HBe-HBeAg-铕标记抗-HBe复合物减少。增强液（β－NTA）将标记在抗体上的Eu3+解离到溶液中，Eu3+和增强液中的有效成分形成高荧光强度的螯合物，荧光强度和样本中的抗-HBe浓度成反比。
